Oral H1N1 influenza vaccine: Phase Ib data

A dose-ranging, open-label, U.S. Phase Ib trial in 24 healthy volunteers showed that Vaxart's oral H1N1 influenza vaccine led to no vaccine-related significant adverse events. Additionally, the vaccin...